NCT03492125View on ClinicalTrials.gov

A Study Of The Selective PKC-β Inhibitor MS- 553

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 25, 2018

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaAggressive Lymphoma
Interventions
DRUG

MS-553

Oral, multiple dose levels

DRUG

MS-553

Oral recommended phase 2 dose of MS-553

DRUG

acalabrutinib

Oral

DRUG

venetoclax

Oral

DRUG

Rituximab

IV

DRUG

obinutuzumab

IV

Trial Locations (5)

10032

Columbia University, Herbert Irving Comprehensive Cancer Center, New York

43210

The Ohio State University, James Comprehensive Cancer Center, Columbus

48109

University Of Michigan Comprehensive Cancer Center, Ann Arbor

77030

MD Anderson Cancer Center, Department of Leukemia, Houston

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors
All Listed Sponsors
lead

MingSight Pharmaceuticals, Inc

INDUSTRY

NCT03492125 - A Study Of The Selective PKC-β Inhibitor MS- 553 | Biotech Hunter | Biotech Hunter